ABCL - AbCellera Biologics Inc.

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Currency in USD

Valuation measures4

Market cap (intra-day) 1.72B
Enterprise value 919.01M
Trailing P/E 11.98
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)3.88
Price/book (mrq)1.40
Enterprise value/revenue 5.08
Enterprise value/EBITDA -69.35

Trading information

Stock price history

Beta (5Y monthly) -0.12
52-week change 3-11.47%
S&P500 52-week change 33.90%
52-week high 314.97
52-week low 35.53
50-day moving average 36.81
200-day moving average 39.62

Share statistics

Avg vol (3-month) 32.07M
Avg vol (10-day) 33.84M
Shares outstanding 5288.73M
Implied shares outstanding 6N/A
Float 8209.67M
% held by insiders 128.64%
% held by institutions 146.48%
Shares short (14 May 2023) 426.62M
Short ratio (14 May 2023) 413.26
Short % of float (14 May 2023) 412.86%
Short % of shares outstanding (14 May 2023) 49.22%
Shares short (prior month 13 Apr 2023) 423.59M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2022
Most-recent quarter (mrq)30 Mar 2023


Profit margin -27.71%
Operating margin (ttm)-40.50%

Management effectiveness

Return on assets (ttm)-2.97%
Return on equity (ttm)-4.15%

Income statement

Revenue (ttm)181.04M
Revenue per share (ttm)0.63
Quarterly revenue growth (yoy)-96.10%
Gross profit (ttm)311.11M
EBITDA -43.95M
Net income avi to common (ttm)-50.16M
Diluted EPS (ttm)-0.18
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)796.49M
Total cash per share (mrq)2.76
Total debt (mrq)83.13M
Total debt/equity (mrq)6.88
Current ratio (mrq)10.50
Book value per share (mrq)4.19

Cash flow statement

Operating cash flow (ttm)133.08M
Levered free cash flow (ttm)85.71M